Hypogonadism Clinical Trial
Official title:
A Randomized Double-blind Placebo-controlled Pilot Trial on the Effects of Testosterone Undecanoate Plus Dutasteride or Placebo on Muscle Strength, Body Composition and Metabolic Profile in Transmen
To compare the effects on body composition and muscle strengthof 54-weeks treatment with of testosterone undecanoate combined with placebo or with the 5a-reductase inhibitor dutasteride
Transmen who have undergone gender-affirming surgery require long-lasting treatments with
androgens to maintain male phenotypic characteristics and to preserve their health. In this
population the effects on muscle and the relative role of testosterone and its metabolite
dihydrotestosterone (DHT) on the skeletal muscle are still largely unknown.
In this pilot study, we evaluated the effects of testosterone and DHT on muscle strength,
body composition, metabolism. Also cutaneous androgenic effects such as acne and androgenetic
alopecia were evaluated.
DESIGN
For this purpose, in this randomized, double-blind placebo-controlled pilot trial we treated
variectomized transmen for 54 weeks with:
- Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + a daily oral
placebo pill (TU+PL)
- TU 1000 mg i.m. at weeks zero, six, 18, 30, 42 + dutasteride 5 mg/day (TU+DUT).
Prospective, phase III, randomized study design was used.
Subjects were seen every 12 weeks for safety monitoring that included evaluation of
hematocrit, transaminases, alkaline phosphatases and bilirubin, creatinine, urea and serum
electrolyte as potassium and sodium.
Baseline and week-54 evaluations included the following measurements:
blood drawings for measurements of: hormonal profile (serum testosterone, estradiol,
luteinizing hormone and follicle-stimulating hormone, prolactin, sex hormone binding
globulin, and thyroid stimulating hormone), haematocrit (Ht) and haemoglobin (Hb), glucidic
and lipidic profile (fasting glucose, fasting insulin, total cholesterol, high- and
low-density lipoproteins, and triglycerides), hepatic function (aspartate and alanine
aminotransferases) and bone related markers (osteocalcin, parathyroid hormone, bone alkaline
phosphatase and 25-hydroxyvitamin, 24h urinary excretion of calcium, potassium, magnesium and
creatinine).
anthropometry: weight, measures DEXA for bone mass determination and body composition
Isokinetic knee extension and flexion peak torque (PT-IKE and PT-IKF) Handgrip strength
evalutation of the psychological profile with the brief Profile of Mood State (POMS) sexual
life satisfaction evalutation with a Visual Analogue General Satisfaction Scale (VAS)
physical examination: inspection of external genitalia (clitorides) and a visit to detect
appearance of acne and gynecomastia
During the treatment phase all injections will be administered by the investigator or
co-investigators for the entire study. Fasting (10 hours) blood samples will be taken
(immediately before giving the injections) every time subjects come for injections (week 0,
6, 18, 30 and 42) and at the end of the treatment phase.
In the sexual and behavior questionnaire the subjects will judge their sexual activity and
behavior in the period between visits. The subjects have the possibility to making additional
comments about important events and disturbances.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03126656 -
Effects of Testosterone on Myocardial Repolarization
|
Phase 4 | |
Terminated |
NCT02419105 -
Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors
|
Phase 3 | |
Withdrawn |
NCT02137265 -
Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism
|
N/A | |
Completed |
NCT02233751 -
Pharmacokinetic Study of Subcutaneous Testosterone Enanthate
|
Phase 1 | |
Completed |
NCT02222558 -
Oral Testosterone for the Treatment of Hypogonadism in Males
|
Phase 2 | |
Completed |
NCT01887418 -
Pharmacokinetic Study of Testosterone Enanthate
|
Phase 1/Phase 2 | |
Terminated |
NCT01092858 -
NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)
|
Phase 4 | |
Completed |
NCT00624624 -
Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism
|
N/A | |
Completed |
NCT00752869 -
Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement
|
Phase 4 | |
Completed |
NCT00613288 -
Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism
|
N/A | |
Completed |
NCT00119483 -
Older Men and Testosterone
|
N/A | |
Completed |
NCT00838838 -
Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis
|
N/A | |
Completed |
NCT00004438 -
Leuprolide in Treating Adults With Hypogonadotropism
|
N/A | |
Withdrawn |
NCT00398034 -
Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study.
|
Phase 2 | |
Completed |
NCT02937740 -
Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natestoâ„¢
|
Phase 4 | |
Completed |
NCT02921386 -
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
|
Phase 2 | |
Completed |
NCT01717768 -
Oral Testosterone for the Treatment of Hypogonadism
|
Phase 2 | |
Terminated |
NCT01460654 -
Testosterone and Alendronate in Hypogonadal Men
|
Phase 2 | |
Completed |
NCT00998933 -
Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure
|
Phase 1 | |
Withdrawn |
NCT00710827 -
Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks
|
Phase 4 |